Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Randolph Hecht

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Clinical Colorectal Cancer|April 10, 2010
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapyJ Randolph Hecht, Madhavan Pillai, Russell Gollard, et al.
Clinical Colorectal Cancer|May 29, 2007
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancerJordan Berlin, James Posey, Simon Tchekmedyian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal AdenocarcinomaElena Elimova, Yelena Y Janjigian, Mary Mulcahy, et al.
Cancer|August 3, 2007
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerJ Randolph Hecht, Amita Patnaik, Jordan Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaJ Randolph Hecht, Rudolph Bedford, James L Abbruzzese, et al.
Cancer Management and Research|June 26, 2015
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb studyJ Randolph Hecht, Edith P Mitchell, Takayuki Yoshino, et al.
International Journal of Colorectal Disease|April 21, 2017
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaFernando Rivera, Meinolf Karthaus, J Randolph Hecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Future Oncology (London, England)|July 23, 2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancerAnwaar Saeed, Josep Tabernero, Aparna Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancerLee S Schwartzberg, Fernando Rivera, Meinolf Karthaus, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Clinical Colorectal Cancer|April 10, 2010
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapyJ Randolph Hecht, Madhavan Pillai, Russell Gollard, et al.
Clinical Colorectal Cancer|May 29, 2007
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancerJordan Berlin, James Posey, Simon Tchekmedyian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal AdenocarcinomaElena Elimova, Yelena Y Janjigian, Mary Mulcahy, et al.
Cancer|August 3, 2007
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerJ Randolph Hecht, Amita Patnaik, Jordan Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaJ Randolph Hecht, Rudolph Bedford, James L Abbruzzese, et al.
Cancer Management and Research|June 26, 2015
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb studyJ Randolph Hecht, Edith P Mitchell, Takayuki Yoshino, et al.
International Journal of Colorectal Disease|April 21, 2017
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaFernando Rivera, Meinolf Karthaus, J Randolph Hecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Future Oncology (London, England)|July 23, 2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancerAnwaar Saeed, Josep Tabernero, Aparna Parikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancerLee S Schwartzberg, Fernando Rivera, Meinolf Karthaus, et al.
Pageof 9